Research Focus

Former Employee. SKI Medicine; Vacation Relief

Recent additions – View all

1. A phase I trial of IGF-1R inhibitor cixutumumab and mTOR inhibitor temsirolimus in metastatic castration-resistant prostate cancer

   Journal Article

   McHugh, D. J.; Chudow, J.; DeNunzio, M.; Slovin, S. F.; Danila, D. C.; Morris, M. J.; Scher, H. I.; Rathkopf, D. E.
   Clinical Genitourinary Cancer (2020)

   Fulltext@MSK | Save
2. A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer

   Journal Article

   Morris, M. J.; Eisenberger, M. A.; Pili, R.; Denmeade, S. R.; Rathkopf, D.; Slovin, S. F.; Farrelly, J.; Chudow, J. J.; Vincent, M.; Scher, H. I.; more...
   Annals of Oncology (2012)

   Fulltext@MSK | Save
3. Anti-insulin-like growth factor-1 receptor (IGF-IR) monoclonal antibody cixutumumab plus mammalian target of rapamycin (mTOR) inhibitor temsirolimus in metastatic castration-resistant prostate cancer (CRPC)

   Meeting Abstract

   Rathkopf, D. E.; Danila, D. C.; Chudow, J. J.; Morris, M. J.; Slovin, S. F.; Fine, S.; Fox, J. J.; Larson, S. M.; Rosen, N.; Scher, H. I.
   Journal of Clinical Oncology (2010)

   Fulltext@MSK | Save